|
KMID : 0988920140120020096
|
|
Intestinal Research
2014 Volume.12 No. 2 p.96 ~ p.102
|
|
|
Corticotropin-releasing Hormone and Its Biological Diversity toward Angiogenesis
|
|
Im Eunok
|
|
|
Abstract
|
|
|
|
Angiogenesis is the formation of new blood vessels from existing ones and an underlying cause of numerous human diseases,including cancer and inflammation. A large body of evidence indicates that angiogenic inhibitors have therapeutic potential inthe treatment of vascular diseases. However, detrimental side effects and low efficacy hinder their use in clinical practice. Membersof the corticotropin-releasing hormone (CRH) family, which comprises CRH, urocortin I?III, and CRH receptors (CRHR)1 and 2, are broadly expressed in the brain and peripheral tissues, including the intestine and cardiovascular system. The CRHfamily regulates stress-related responses through the hypothalamic-pituitary-adrenal axis. Therapeutic agents that target CRHfamily members offer a new approach to the treatment of various gastrointestinal disorders, including irritable bowel syndrome(IBS), inflammatory bowel disease (IBD), and colorectal cancer. Since the discovery that CRHR 2 has anti-angiogenic activityduring postnatal development in mice, studies have focused on the role of the CRH system in the modulation of blood vesselformation and cardiovascular function. This review will outline the basic biological functions of the CRH family members andthe implications for the development of novel anti-angiogenic therapies. (Intest Res 2014;12:96-102)
|
|
|
KEYWORD
|
|
|
Corticotropin-releasing hormone, Angiogenesis, Urocortins
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|